Many co-stimulatory and inhibitory molecules were found increased expression in low-risk patients, as well as T cell activation markers such as KLRG1, which might imply a hyporesponsive state of T cells in tumor-killing activities that decrease tumor burden to improve survival. This evidence concerns the gene KLRG1 and neoplasm.